While several genetic and morphological markers are established and serve to guide
therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional …

Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML)
and 13 control cases using immunohistochemistry. Methods: CD105 expression was …

Endoglin (CD105), a receptor of the transforming growth factor-beta superfamily, is
considered a powerful marker of angiogenesis and a potential main player in the …

Genetic and morphological markers are well-established prognostic factors in acute myeloid
leukemia (AML). However, further reliable markers are urgently needed to improve risk …

Background The aim of this study was to analyze the level of CD33 expression in patients
with newly diagnosed AML and determine its correlation with clinical characteristics …

Purpose Extensive studies have investigated the prognostic value of CD56 for patients with
acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta …

Acute myeloid leukemia (AML) is a heterogeneous group of disorders with distinct
characteristics and prognoses. Although cytogenetic changes and gene mutations are …

Angiogenesis is crucial for tumor development and progression, and antiangiogenetic
therapy represents a promising approach for cancer treatment. Thus, the in-depth …

Overexpression of CD200, a trans-membrane protein belonging to the immunoglobulin
superfamily, has been associated with poor prognosis in patients with acute myeloid …

Neural cell adhesion molecule (NCAM/CD56) expression in acute myeloid leukemia (AML)
has been associated with extramedullary leukemia, multidrug resistance, shorter remission …